Acute safety and efficacy of the NeoChord procedure

OBJECTIVES Transapical off-pump mitral valve repair using the NeoChord device has been proposed to treat degenerative mitral valve regurgitation. This prospective study sought to evaluate acute safety and efficacy of this innovative, minimally invasive, transcatheter mitral valve repair approach. ME...

Full description

Saved in:
Bibliographic Details
Published inInteractive cardiovascular and thoracic surgery Vol. 20; no. 5; pp. 575 - 581
Main Authors Colli, Andrea, Manzan, Erica, Rucinskas, Kestutis, Janusauskas, Vilius, Zucchetta, Fabio, Zakarkaitė, Diana, Aidietis, Audrius, Gerosa, Gino
Format Journal Article
LanguageEnglish
Published England Oxford University Press 01.05.2015
Subjects
Online AccessGet full text
ISSN1569-9293
1569-9285
1569-9285
DOI10.1093/icvts/ivv014

Cover

Abstract OBJECTIVES Transapical off-pump mitral valve repair using the NeoChord device has been proposed to treat degenerative mitral valve regurgitation. This prospective study sought to evaluate acute safety and efficacy of this innovative, minimally invasive, transcatheter mitral valve repair approach. METHODS Symptomatic patients with severe mitral regurgitation (MR) were selected if they presented a favourable valve anatomy (the presence of leaflet flail/prolapse with consistent overlap of tissue). Early device success was defined as placement of at least two neochordae with residual mitral regurgitation ≤2+ after the procedure. The primary acute safety and efficacy end points were evaluated at 30 days. RESULTS Between February 2013 and June 2014, in Padua and Vilnius University Hospitals, a total of 62 patients were treated, with a median age of 66 years (IQR 52–76) and a median EuroSCORE I of 1.9% (IQR 0.9–6). Fifty-six patients (88.9%) presented with a posterior leaflet prolapse, 4 (6%) with an anterior leaflet prolapse and 3 (5%) with a combined disease. Early procedural success was achieved in all patients. Two neochordae were implanted in 2 patients (3%), 3 in 20 (32%), 4 in 28 (44%), 5 in 10 (16%), 6 in 2 (3%) and 7 in 1 (2%). At 30 days, major adverse events included only 1 acute myocardial infarction (2%) successfully treated percutaneously and 2 cases of sepsis (3%). Mitral regurgitation at 30 days was absent in 29 patients (46%), Grade 1+ in 16 (25%), Grade 2+ in 10 (16%), Grade 3+ in 7 (11%) and Grade 4+ in 1 (2%). All 8 patients with MR >2+ were successfully reoperated with conventional surgery or NeoChord reintervention. CONCLUSIONS Initial results with the NeoChord procedure in a small number of patients indicate that transapical off-pump mitral valve repair is feasible and safe. Efficacy is maintained up to the 30-day follow-up with significant clinical benefit for patients.
AbstractList Transapical off-pump mitral valve repair using the NeoChord device has been proposed to treat degenerative mitral valve regurgitation. This prospective study sought to evaluate acute safety and efficacy of this innovative, minimally invasive, transcatheter mitral valve repair approach.OBJECTIVESTransapical off-pump mitral valve repair using the NeoChord device has been proposed to treat degenerative mitral valve regurgitation. This prospective study sought to evaluate acute safety and efficacy of this innovative, minimally invasive, transcatheter mitral valve repair approach.Symptomatic patients with severe mitral regurgitation (MR) were selected if they presented a favourable valve anatomy (the presence of leaflet flail/prolapse with consistent overlap of tissue). Early device success was defined as placement of at least two neochordae with residual mitral regurgitation ≤ 2+ after the procedure. The primary acute safety and efficacy end points were evaluated at 30 days.METHODSSymptomatic patients with severe mitral regurgitation (MR) were selected if they presented a favourable valve anatomy (the presence of leaflet flail/prolapse with consistent overlap of tissue). Early device success was defined as placement of at least two neochordae with residual mitral regurgitation ≤ 2+ after the procedure. The primary acute safety and efficacy end points were evaluated at 30 days.Between February 2013 and June 2014, in Padua and Vilnius University Hospitals, a total of 62 patients were treated, with a median age of 66 years (IQR 52-76) and a median EuroSCORE I of 1.9% (IQR 0.9-6). Fifty-six patients (88.9%) presented with a posterior leaflet prolapse, 4 (6%) with an anterior leaflet prolapse and 3 (5%) with a combined disease. Early procedural success was achieved in all patients. Two neochordae were implanted in 2 patients (3%), 3 in 20 (32%), 4 in 28 (44%), 5 in 10 (16%), 6 in 2 (3%) and 7 in 1 (2%). At 30 days, major adverse events included only 1 acute myocardial infarction (2%) successfully treated percutaneously and 2 cases of sepsis (3%). Mitral regurgitation at 30 days was absent in 29 patients (46%), Grade 1+ in 16 (25%), Grade 2+ in 10 (16%), Grade 3+ in 7 (11%) and Grade 4+ in 1 (2%). All 8 patients with MR >2+ were successfully reoperated with conventional surgery or NeoChord reintervention.RESULTSBetween February 2013 and June 2014, in Padua and Vilnius University Hospitals, a total of 62 patients were treated, with a median age of 66 years (IQR 52-76) and a median EuroSCORE I of 1.9% (IQR 0.9-6). Fifty-six patients (88.9%) presented with a posterior leaflet prolapse, 4 (6%) with an anterior leaflet prolapse and 3 (5%) with a combined disease. Early procedural success was achieved in all patients. Two neochordae were implanted in 2 patients (3%), 3 in 20 (32%), 4 in 28 (44%), 5 in 10 (16%), 6 in 2 (3%) and 7 in 1 (2%). At 30 days, major adverse events included only 1 acute myocardial infarction (2%) successfully treated percutaneously and 2 cases of sepsis (3%). Mitral regurgitation at 30 days was absent in 29 patients (46%), Grade 1+ in 16 (25%), Grade 2+ in 10 (16%), Grade 3+ in 7 (11%) and Grade 4+ in 1 (2%). All 8 patients with MR >2+ were successfully reoperated with conventional surgery or NeoChord reintervention.Initial results with the NeoChord procedure in a small number of patients indicate that transapical off-pump mitral valve repair is feasible and safe. Efficacy is maintained up to the 30-day follow-up with significant clinical benefit for patients.CONCLUSIONSInitial results with the NeoChord procedure in a small number of patients indicate that transapical off-pump mitral valve repair is feasible and safe. Efficacy is maintained up to the 30-day follow-up with significant clinical benefit for patients.
OBJECTIVES Transapical off-pump mitral valve repair using the NeoChord device has been proposed to treat degenerative mitral valve regurgitation. This prospective study sought to evaluate acute safety and efficacy of this innovative, minimally invasive, transcatheter mitral valve repair approach. METHODS Symptomatic patients with severe mitral regurgitation (MR) were selected if they presented a favourable valve anatomy (the presence of leaflet flail/prolapse with consistent overlap of tissue). Early device success was defined as placement of at least two neochordae with residual mitral regurgitation ≤2+ after the procedure. The primary acute safety and efficacy end points were evaluated at 30 days. RESULTS Between February 2013 and June 2014, in Padua and Vilnius University Hospitals, a total of 62 patients were treated, with a median age of 66 years (IQR 52–76) and a median EuroSCORE I of 1.9% (IQR 0.9–6). Fifty-six patients (88.9%) presented with a posterior leaflet prolapse, 4 (6%) with an anterior leaflet prolapse and 3 (5%) with a combined disease. Early procedural success was achieved in all patients. Two neochordae were implanted in 2 patients (3%), 3 in 20 (32%), 4 in 28 (44%), 5 in 10 (16%), 6 in 2 (3%) and 7 in 1 (2%). At 30 days, major adverse events included only 1 acute myocardial infarction (2%) successfully treated percutaneously and 2 cases of sepsis (3%). Mitral regurgitation at 30 days was absent in 29 patients (46%), Grade 1+ in 16 (25%), Grade 2+ in 10 (16%), Grade 3+ in 7 (11%) and Grade 4+ in 1 (2%). All 8 patients with MR >2+ were successfully reoperated with conventional surgery or NeoChord reintervention. CONCLUSIONS Initial results with the NeoChord procedure in a small number of patients indicate that transapical off-pump mitral valve repair is feasible and safe. Efficacy is maintained up to the 30-day follow-up with significant clinical benefit for patients.
Transapical off-pump mitral valve repair using the NeoChord device has been proposed to treat degenerative mitral valve regurgitation. This prospective study sought to evaluate acute safety and efficacy of this innovative, minimally invasive, transcatheter mitral valve repair approach. Symptomatic patients with severe mitral regurgitation (MR) were selected if they presented a favourable valve anatomy (the presence of leaflet flail/prolapse with consistent overlap of tissue). Early device success was defined as placement of at least two neochordae with residual mitral regurgitation ≤ 2+ after the procedure. The primary acute safety and efficacy end points were evaluated at 30 days. Between February 2013 and June 2014, in Padua and Vilnius University Hospitals, a total of 62 patients were treated, with a median age of 66 years (IQR 52-76) and a median EuroSCORE I of 1.9% (IQR 0.9-6). Fifty-six patients (88.9%) presented with a posterior leaflet prolapse, 4 (6%) with an anterior leaflet prolapse and 3 (5%) with a combined disease. Early procedural success was achieved in all patients. Two neochordae were implanted in 2 patients (3%), 3 in 20 (32%), 4 in 28 (44%), 5 in 10 (16%), 6 in 2 (3%) and 7 in 1 (2%). At 30 days, major adverse events included only 1 acute myocardial infarction (2%) successfully treated percutaneously and 2 cases of sepsis (3%). Mitral regurgitation at 30 days was absent in 29 patients (46%), Grade 1+ in 16 (25%), Grade 2+ in 10 (16%), Grade 3+ in 7 (11%) and Grade 4+ in 1 (2%). All 8 patients with MR >2+ were successfully reoperated with conventional surgery or NeoChord reintervention. Initial results with the NeoChord procedure in a small number of patients indicate that transapical off-pump mitral valve repair is feasible and safe. Efficacy is maintained up to the 30-day follow-up with significant clinical benefit for patients.
Author Manzan, Erica
Aidietis, Audrius
Janusauskas, Vilius
Colli, Andrea
Zucchetta, Fabio
Rucinskas, Kestutis
Zakarkaitė, Diana
Gerosa, Gino
Author_xml – sequence: 1
  givenname: Andrea
  surname: Colli
  fullname: Colli, Andrea
  email: colli.andrea.bcn@gmail.com
  organization: University of Padua
– sequence: 2
  givenname: Erica
  surname: Manzan
  fullname: Manzan, Erica
  organization: University of Padua
– sequence: 3
  givenname: Kestutis
  surname: Rucinskas
  fullname: Rucinskas, Kestutis
  organization: University of Vilnius
– sequence: 4
  givenname: Vilius
  surname: Janusauskas
  fullname: Janusauskas, Vilius
  organization: University of Vilnius
– sequence: 5
  givenname: Fabio
  surname: Zucchetta
  fullname: Zucchetta, Fabio
  organization: University of Padua
– sequence: 6
  givenname: Diana
  surname: Zakarkaitė
  fullname: Zakarkaitė, Diana
  organization: University of Vilnius
– sequence: 7
  givenname: Audrius
  surname: Aidietis
  fullname: Aidietis, Audrius
  organization: University of Vilnius
– sequence: 8
  givenname: Gino
  surname: Gerosa
  fullname: Gerosa, Gino
  organization: University of Padua
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25690455$$D View this record in MEDLINE/PubMed
BookMark eNp9kL1PwzAQxS1URD9gY0bZYCDUsWM3HquKL6mCBebIsc-qURoX26nU_57QlA5IMN1J93vv6d4YDRrXAEKXGb7LsKBTq7YxTO12i7P8BI0yxkUqSMEGx13QIRqH8IFxJjDFZ2hIugPOGRshOldthCRIA3GXyEYnYIxVUu0SZ5K4guQF3GLlvE423inQrYdzdGpkHeDiMCfo_eH-bfGULl8fnxfzZaooz2KqDBGS64JJ4AqqQlDJC41nitBcaGBMVKoqqO7CRMWM4QwEIcLkUGhJOKETdNP7dsmfLYRYrm1QUNeyAdeGMuMzTnMs9ujVAW2rNehy4-1a-l3582gH3PaA8i4ED-aIZLj87rHc91j2PXY4-YUrG2W0role2vov0XUvcu3mf_svpUyGIQ
CitedBy_id crossref_primary_10_1161_CIRCULATIONAHA_116_024797
crossref_primary_10_1016_j_repc_2021_01_016
crossref_primary_10_1111_jocs_15350
crossref_primary_10_1161_JAHA_117_006309
crossref_primary_10_3389_fcvm_2023_1166892
crossref_primary_10_1093_icvts_ivv192
crossref_primary_10_3390_bioengineering7010025
crossref_primary_10_5847_wjem_j_1920_8642_2019_03_001
crossref_primary_10_1016_j_circv_2023_03_004
crossref_primary_10_1093_ejcts_ezx250
crossref_primary_10_1007_s00540_016_2251_9
crossref_primary_10_1097_HCO_0000000000000825
crossref_primary_10_1161_CIRCULATIONAHA_114_014023
crossref_primary_10_1213_ANE_0000000000002767
crossref_primary_10_1080_17434440_2021_1940141
crossref_primary_10_1053_j_jvca_2016_06_031
crossref_primary_10_1007_s10047_023_01383_2
crossref_primary_10_1016_j_ijcard_2018_01_049
crossref_primary_10_1111_jocs_13120
crossref_primary_10_3389_fcvm_2023_1120323
crossref_primary_10_1016_j_repce_2021_11_011
crossref_primary_10_1093_ejcts_ezz164
crossref_primary_10_1186_s12872_019_01312_3
crossref_primary_10_3389_fcvm_2022_985644
crossref_primary_10_1177_15569845231178718
crossref_primary_10_3390_ma15093302
crossref_primary_10_1177_1089253218779787
crossref_primary_10_1016_j_athoracsur_2018_01_092
crossref_primary_10_1016_j_echo_2018_01_011
crossref_primary_10_1016_j_xjon_2020_05_010
crossref_primary_10_1093_ejcts_ezz048
crossref_primary_10_3389_fcvm_2019_00088
crossref_primary_10_1016_j_medengphy_2019_09_014
crossref_primary_10_1093_ejcts_ezy046
crossref_primary_10_1007_s13239_024_00764_9
crossref_primary_10_1177_155698451801300307
crossref_primary_10_1016_j_medengphy_2022_103773
crossref_primary_10_1007_s10439_020_02464_6
crossref_primary_10_1016_j_amcp_2016_11_003
crossref_primary_10_1016_j_ijcard_2018_01_026
crossref_primary_10_1016_j_jtcvs_2020_12_142
crossref_primary_10_1111_jocs_16011
crossref_primary_10_1111_jocs_16330
crossref_primary_10_3389_fcvm_2019_00128
crossref_primary_10_1038_s41598_019_41173_6
crossref_primary_10_1093_ejcts_ezw188
crossref_primary_10_1097_imi_0000000000000506
crossref_primary_10_3390_bioengineering10050601
crossref_primary_10_1016_j_ijcard_2015_11_131
crossref_primary_10_3390_jcm11123377
crossref_primary_10_1016_j_athoracsur_2019_01_053
crossref_primary_10_1016_j_jtcvs_2020_11_105
crossref_primary_10_15420_icr_2019_13_R1
crossref_primary_10_1016_j_athoracsur_2016_05_052
Cites_doi 10.1097/IMI.0b013e31816d3d08
10.1016/j.ejcts.2011.03.058
10.1016/j.jacc.2013.07.090
10.1161/hc2601.093182
10.1016/j.athoracsur.2007.03.058
10.1016/j.athoracsur.2013.09.077
10.1016/j.jcmg.2014.01.003
10.1016/j.jtcvs.2005.06.046
10.1016/j.jtcvs.2013.07.068
10.1161/01.CIR.92.4.811
10.1093/ejcts/ezs455
10.1016/j.jtcvs.2013.08.012
10.1016/j.jtcvs.2008.09.004
10.1016/j.jtcvs.2009.03.057
10.1016/j.athoracsur.2008.05.015
10.1016/j.athoracsur.2009.03.003
10.1161/CIRCIMAGING.112.000098
ContentType Journal Article
Copyright The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. 2015
The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
Copyright_xml – notice: The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. 2015
– notice: The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1093/icvts/ivv014
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 1569-9285
EndPage 581
ExternalDocumentID 25690455
10_1093_icvts_ivv014
10.1093/icvts/ivv014
Genre Journal Article
Observational Study
GroupedDBID ---
--K
0R~
18M
1B1
29J
2WC
4.4
48X
53G
5GY
AAIYJ
AAJKP
AAOGV
AAPXW
AAVAP
ABKDP
ABNKS
ABOCM
ABPTD
ABQLI
ABXVV
ABZBJ
ACGFO
ACGFS
ADBBV
ADEYI
ADHKW
ADJQC
ADOCK
ADRIX
ADRTK
ADYVW
ADZXQ
AEGPL
AEJOX
AEKSI
AENEX
AEPUE
AFOFC
AFULF
AFXEN
AGINJ
ALMA_UNASSIGNED_HOLDINGS
AWCFO
AXUDD
BAWUL
BAYMD
BHONS
C1A
CS3
DIK
DPORF
DPPUQ
DU5
E3Z
EBD
EBS
EE~
EJD
EMOBN
F5P
F9B
GX1
H13
H5~
HZ~
IHE
J5H
KBUDW
KSI
M41
M~E
NQ-
O9-
OK1
O~Y
RIG
RNS
ROL
ROX
RPM
RPZ
RXO
SEW
SV3
TEU
TJX
TOX
TR2
UHS
W8F
WOQ
XSB
ZCN
AAFWJ
AAYXX
ABEJV
ABGNP
AMNDL
CITATION
OVT
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c361t-cf29a6d85ae6ceb893a68d07c2349de559bcb83dcac9b5ff65e9229f4e8da2623
IEDL.DBID TOX
ISSN 1569-9293
1569-9285
IngestDate Fri Jul 11 07:24:52 EDT 2025
Thu Apr 03 06:57:54 EDT 2025
Tue Jul 01 03:55:23 EDT 2025
Thu Apr 24 23:01:07 EDT 2025
Wed Sep 11 04:48:41 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Mitral valve
NeoChord procedure
Mitral valve repair
Off-pump
Regurgitation
Language English
License The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c361t-cf29a6d85ae6ceb893a68d07c2349de559bcb83dcac9b5ff65e9229f4e8da2623
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://academic.oup.com/icvts/article-pdf/20/5/575/6124816/ivv014.pdf
PMID 25690455
PQID 1676340962
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_1676340962
pubmed_primary_25690455
crossref_primary_10_1093_icvts_ivv014
crossref_citationtrail_10_1093_icvts_ivv014
oup_primary_10_1093_icvts_ivv014
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20150500
2015-05-00
2015-May
20150501
PublicationDateYYYYMMDD 2015-05-01
PublicationDate_xml – month: 05
  year: 2015
  text: 20150500
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Interactive cardiovascular and thoracic surgery
PublicationTitleAlternate Interact Cardiovasc Thorac Surg
PublicationYear 2015
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References 2015091108351374000_20.5.575.9
2015091108351374000_20.5.575.19
2015091108351374000_20.5.575.18
2015091108351374000_20.5.575.1
2015091108351374000_20.5.575.17
2015091108351374000_20.5.575.2
2015091108351374000_20.5.575.16
2015091108351374000_20.5.575.3
2015091108351374000_20.5.575.15
2015091108351374000_20.5.575.4
2015091108351374000_20.5.575.14
2015091108351374000_20.5.575.5
2015091108351374000_20.5.575.13
2015091108351374000_20.5.575.6
2015091108351374000_20.5.575.12
2015091108351374000_20.5.575.7
2015091108351374000_20.5.575.11
2015091108351374000_20.5.575.8
2015091108351374000_20.5.575.10
References_xml – ident: 2015091108351374000_20.5.575.19
  doi: 10.1097/IMI.0b013e31816d3d08
– ident: 2015091108351374000_20.5.575.10
  doi: 10.1016/j.ejcts.2011.03.058
– ident: 2015091108351374000_20.5.575.11
  doi: 10.1016/j.jacc.2013.07.090
– ident: 2015091108351374000_20.5.575.2
  doi: 10.1161/hc2601.093182
– ident: 2015091108351374000_20.5.575.16
  doi: 10.1016/j.athoracsur.2007.03.058
– ident: 2015091108351374000_20.5.575.17
  doi: 10.1016/j.athoracsur.2013.09.077
– ident: 2015091108351374000_20.5.575.7
  doi: 10.1016/j.jcmg.2014.01.003
– ident: 2015091108351374000_20.5.575.5
  doi: 10.1016/j.jtcvs.2005.06.046
– ident: 2015091108351374000_20.5.575.18
  doi: 10.1016/j.jtcvs.2013.07.068
– ident: 2015091108351374000_20.5.575.15
  doi: 10.1161/01.CIR.92.4.811
– ident: 2015091108351374000_20.5.575.1
  doi: 10.1093/ejcts/ezs455
– ident: 2015091108351374000_20.5.575.12
  doi: 10.1016/j.jtcvs.2013.08.012
– ident: 2015091108351374000_20.5.575.4
– ident: 2015091108351374000_20.5.575.8
  doi: 10.1016/j.jtcvs.2008.09.004
– ident: 2015091108351374000_20.5.575.9
  doi: 10.1016/j.jtcvs.2009.03.057
– ident: 2015091108351374000_20.5.575.3
  doi: 10.1016/j.athoracsur.2008.05.015
– ident: 2015091108351374000_20.5.575.6
  doi: 10.1016/j.athoracsur.2009.03.003
– ident: 2015091108351374000_20.5.575.13
– ident: 2015091108351374000_20.5.575.14
  doi: 10.1161/CIRCIMAGING.112.000098
SSID ssj0019030
Score 2.3095338
Snippet OBJECTIVES Transapical off-pump mitral valve repair using the NeoChord device has been proposed to treat degenerative mitral valve regurgitation. This...
Transapical off-pump mitral valve repair using the NeoChord device has been proposed to treat degenerative mitral valve regurgitation. This prospective study...
SourceID proquest
pubmed
crossref
oup
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 575
SubjectTerms Aged
Cardiac Catheterization - methods
Chordae Tendineae - surgery
Cohort Studies
Echocardiography, Transesophageal - methods
Feasibility Studies
Female
Follow-Up Studies
Heart Valve Prosthesis
Heart Valve Prosthesis Implantation - methods
Hospitals, University
Humans
Italy
Length of Stay
Male
Middle Aged
Minimally Invasive Surgical Procedures - methods
Mitral Valve Insufficiency - diagnostic imaging
Mitral Valve Insufficiency - physiopathology
Mitral Valve Insufficiency - surgery
Patient Safety
Postoperative Complications - physiopathology
Prospective Studies
Prosthesis Design
Prosthesis Failure
Treatment Outcome
Title Acute safety and efficacy of the NeoChord procedure
URI https://www.ncbi.nlm.nih.gov/pubmed/25690455
https://www.proquest.com/docview/1676340962
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1La8MwDDajp13Gxl7dCw-20wht7cSxj6VslMG6Swu9BcdWWGEko0kK_feTnbTQPeglJ8XGsvD3ybIkQh7QaiQwV09bAH4Yg8ClbwbAJdMytSL0d7pvEzGeha_zaN4WSSr_COEr3luYVVX2FqtV3zesRvx19jx9n2-jBarve4qgK6IChHvePnD_-fMO9Oyks_1ilR5dXo7JUUsL6bDZxxNyAPkp4UNTV0BLnUG1pujyU3AFH7RZ0yKjyNzoBIrRB7qP1OOQrZdwRmYvz9PROGibHASGi0EVmIwpLayMNAgDKdIHLaTtx4bxUFlAwp-aVHKLg6s0yjIRgWJMZSFIqxmSl3PSyYscLgllWRTGsbJSu3s99HuN1pGWKlYunRZ4lzxt1p-YtgK4a0TxmTSRaJ54bSWNtrrkcSv91VS--EeOoir3iNxv9Jyg9bqQhM6hqMtkIPB8Q3MQrEsumg3YjoRkTCHhjK72T3BNDplLS_AP825Ip1rWcItkoUrvvKV8A2CsvNA
linkProvider Oxford University Press
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acute+safety+and+efficacy+of+the+NeoChord+procedure&rft.jtitle=Interactive+cardiovascular+and+thoracic+surgery&rft.au=Colli%2C+Andrea&rft.au=Manzan%2C+Erica&rft.au=Rucinskas%2C+Kestutis&rft.au=Janusauskas%2C+Vilius&rft.date=2015-05-01&rft.pub=Oxford+University+Press&rft.issn=1569-9293&rft.eissn=1569-9285&rft.volume=20&rft.issue=5&rft.spage=575&rft.epage=581&rft_id=info:doi/10.1093%2Ficvts%2Fivv014&rft.externalDocID=10.1093%2Ficvts%2Fivv014
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1569-9293&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1569-9293&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1569-9293&client=summon